BMS Archive

Plant · Scientific monograph

Aloe vera

Aloe vera

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Skin health, Digestive health

Research overview

Historical use

Aloe has documented historical skin and wound use in several ancient medical traditions. Historical use is not evidence that contemporary gel, latex and whole-leaf products have equivalent effects [4].

Modern research context

Aloe gel preparations have been investigated for wounds and oral inflammatory-bowel symptoms, with substantial uncertainty and product differences [1][2][5]. A small 4-week UC trial (44 evaluable participants) found more clinical responses with oral gel than placebo, but clinical remission and sigmoidoscopic findings were not convincingly different [1]. The 2012 wound review found insufficient high-quality evidence [2]. A later review of nine burn RCTs reported shorter healing with aloe preparations, while pain and infection differences were not significant; these burn findings cannot be generalized to all wounds or products [5]. BMS Level C for the exploratory UC signal, provisional B for the narrower burn-healing outcome pending full-text quality appraisal, and U for a firm broad wound-healing conclusion. Gel findings do not support oral latex or whole-leaf products.

Adverse effects

Topical gel may cause burning, itching or rash. Oral latex causes cramps and diarrhea. Acute hepatitis has been associated with oral aloe preparations, whose exact plant fraction may be unclear [3][4].

Contraindications

Known aloe hypersensitivity precludes the relevant product. Oral aloe is discouraged in pregnancy and lactation. Gel research must not be generalized to anthranoid-containing latex/whole-leaf laxatives; obstruction or unexplained abdominal symptoms require clinical assessment, not self-treatment [4].

Clinical and phytochemical data

Used part

Inner-leaf gel in the UC trial and varied topical products in wound research. Latex is the outer-leaf exudate; whole-leaf extracts contain different fractions and require separate safety assessment [1][2][4].

Primary active compounds

  • Inner-leaf gel is a complex preparation; its clinical constituent standardization is not established in the retrieved trial abstract [1].

  • Aloin is an anthraquinone constituent relevant to oral aloe-product safety; gel, latex and whole-leaf extracts require separate assessment [4].

Mechanism of action

Inflammatory activity was assessed clinically/histologically in the small gel trial; it does not establish a molecular mechanism. No specific receptor or signaling target is attributed from these clinical sources [1].

Pharmacokinetics

Absorption

Human absorption/bioavailability of the studied whole gel is not characterized in retrieved sources; no intact-polysaccharide systemic exposure assumed [1][4].

Distribution

Human tissue distribution of the gel preparation is unknown in this extraction [1][4].

Metabolism

Human gel-product metabolic pathways are insufficiently characterized; anthranoid pharmacology cannot be assigned to anthranoid-depleted gel [4].

Excretion

No validated gel-product elimination route or half-life identified in the retrieved literature [1][4].

Safety and interactions

Drug interactions

NCCIH flags increased cardiac-glycoside adverse-effect risk with latex overuse. This is preparation specific and must not be automatically assigned to topical inner-leaf gel [4].

Toxicity

Oral aloe preparations have been associated with hepatitis [3]. Non-decolorized whole-leaf extracts produced GI tumors in rodents; this is animal evidence and not interchangeable with inner gel or a quantified human cancer risk [4].

Special precautions

Pregnancy

Oral gel, latex and whole-leaf products may be unsafe during pregnancy per NCCIH; topical pregnancy evidence is insufficiently characterized here [4].

Lactation

Oral aloe may be unsafe while breastfeeding; infant exposure for specific products is inadequately characterized [4].

Hepatic impairment

Hepatitis reports warrant particular caution with oral products; no validated hepatic adjustment exists in these sources [3][4].

Renal impairment

Renal-impairment safety is inadequately characterized in the selected sources. Diarrhea-producing oral products warrant particular caution because of fluid losses; this is a precautionary inference, not a tested renal dosing rule [4].

Sources and references

  1. [1] - Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Alimentary pharmacology & therapeutics 2004. PMID: 15043514. DOI: 10.1111/j.1365-2036.2004.01902.x.
  2. [2] - Dat AD, Poon F, Pham KB, Doust J. Aloe vera for treating acute and chronic wounds. The Cochrane database of systematic reviews 2012. PMID: 22336851. DOI: 10.1002/14651858.cd008762.pub2.
  3. [3] - Lee J, Lee MS, Nam KW. Acute toxic hepatitis caused by an aloe vera preparation in a young patient: a case report with a literature review. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2014. PMID: 25073673. DOI: 10.4166/kjg.2014.64.1.54.
  4. [4] - NCCIH. Aloe Vera: Usefulness and Safety. https://www.nccih.nih.gov/health/aloe-vera Accessed 2026-10-25.
  5. [5] - Huang YN, Chen KC, Wang JH, Lin YK. Effects of Aloe vera on Burn Injuries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Burn Care & Research 2024;45:1536–1545. PMID: 38605441. DOI: 10.1093/jbcr/irae061. Abstract reviewed; full-text appraisal pending.

Additional source links

Continue browsing